The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: Studies using concurrent high-resolution manometry and videofluoroscopy

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 7, 2006, Pages 1017-1027

  Fox, M ^a   Menne, D ^b   Stutz, B ^a   Fried, M ^a   Schwizer, W ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Menne Biomed   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TEGASEROD;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; ESOPHAGUS FUNCTION; ESOPHAGUS MOTILITY; FEMALE; FLUOROSCOPY; GASTROESOPHAGEAL REFLUX; HUMAN; LOWER ESOPHAGUS SPHINCTER PRESSURE; MALE; MANOMETRY; NORMAL HUMAN; PERISTALSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TEST MEAL;

ADULT; DOUBLE-BLIND METHOD; ESOPHAGUS; FEMALE; FLUOROSCOPY; GASTROINTESTINAL AGENTS; HUMANS; INDOLES; MALE; MANOMETRY;

EID: 33748659871     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03090.x     Document Type: Article

References (32)

1. Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther 2001; 15: 277-89.
2. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-66.
3. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463-8.
4. Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15: 1745-51.
5. Horowitz M, Maddox A, Harding PE, et al. Effect of cisapride on gastric and esophageal emptying in insulin-dependent diabetes mellitus. Gastroenterology 1987; 92: 1899-907.
6. Wiseman LR, Faulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994; 47: 116-52.
7. Griffin JP. Prepulsid withdrawn from UK & US markets. Adverse Drug React Toxicol Rev 2000; 19: 177.
8. Morganroth J, Ruegg PC, Dunger-Baldauf C, et al. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am J Gastroenterol 2002; 97: 2321-7.
9. Kahrilas PJ, Quigley EM, Castell DO, Spechler SJ. The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 1503-9.
10. Freidin N, Mittal RK, Traube M, McCallum RW. Segmental high amplitude peristaltic contractions in the distal esophagus. Am J Gastroenterol 1989; 84: 619-23.
11. Traube M, Peterson J, Siskind BN, McCallum RW. "Segmental aperistalsis" of the esophagus: a cause of chest pain and dysphagia. Am J Gastroenterol 1988; 83: 1381-5.
12. Massey BT, Dodds WJ, Hogan WJ, Brasseur JG, Helm JF. Abnormal esophageal motility. An analysis of concurrent radiographic and manometric findings. Gastroenterology 1991; 101: 344-54.
13. Brasseur JG, Dodds WJ. Interpretation of intraluminal manometric measurements in terms of swallowing mechanics. Dysphagia 1991; 6: 100-19.
14. Ghosh SK, Pandolfino JE, Zhang Q, Jarosz A, Shah N, Kahrilas PJ. Quantifying Esophageal Peristalsis with High-Resolution Manometry: a study of 75 asymptomatic volunteers. Am J Physiol Gastrointest Liver Physiol 2006; 290: G988-97.
15. Fox M, Hebbard G, Janiak P, et al. High-resolution manometry predicts the success of oesophageal bolus transport and identifies clinically important abnormalities not detected by conventional manometry. Neurogastroenterol Motil 2004; 16: 533-42.
16. Tutuian R, Castell DO. Combined multi-channel intraluminal impedance and manometry clarifies esophageal function abnormalities: study in 350 patients. Am J Gastroenterol 2004; 99: 1011-9.
17. Bredenoord AJ, Weusten BL, Curvers WL, Timmer R, Smout AJ. Determinants of perception of heartburn and regurgitation. Gut 2006; 55: 313-8.
18. Pouderoux P, Shi G, Tatum RP, Kahrilas PJ. Esophageal solid bolus transit: studies using concurrent videofluoroscopy and manometry. Am J Gastroenterol 1999; 94: 1457-63.
19. Meshkinpour H, Eckerling G. Unexplained dysphagia: viscous swallow-induced esophageal dysmotility. Dysphagia 1996; 11: 125-8.
20. Ghosh SK, Janiak P, Schwizer W, Hebbard GS, Brasseur JG. Physiology of the esophageal pressure transition zone: separate contraction waves above and below. Am J Physiol Gastrointest Liver Physiol 2006; 290: G568-76.
21. Holloway RH, Penagini R, Ireland AC. Criteria for objective definition of transient lower esophageal sphincter relaxation. Am J Physiol 1995; 268: G128-33.
22. Clouse R, Staiano A. Topography of the esophageal peristaltic pressure wave. Am J Physiol Gastroint Liver Physiol 1991; 261: G677-84.
23. Fox M. Bravo vs. catheter pH monitoring. Gut 2006; 55: 434-5.
24. Trudgill NJ, Hussain FN, Moustafa M, Ajjan R, D'Amato M, Riley SA. The effect of cholecystokinin antagonism on postprandial lower oesophageal sphincter function in asymptomatic volunteers and patients with reflux disease. Aliment Pharmacol Ther 2001; 15: 1357-64.
25. Dooley CP, Schlossmacher B, Valenzuela JE. Modulation of esophageal peristalsis by alterations of body position. Effect of bolus viscosity. Dig Dis Sci 1989; 34: 1662-7.
26. Tutuian R, Elton JP, Castell DO, Gideon RM, Castell JA, Katz PO. Effects of position on oesophageal function: studies using combined manometry and multi-channel intraluminal impedance. Neurogastroenterol Motil 2003; 15: 63-7.
27. Pandolfino JE, Shi G, Curry J, Joehl RJ, Brasseur JG, Kahrilas PJ. Esophagogastric junction distensibility: a factor contributing to sphincter incompetence. Am J Physiol Gastrointest Liver Physiol 2002; 282: G1052-8.
28. Staiano A, Clouse RE. The effects of cisapride on the topography of oesophageal peristalsis. Aliment Pharmacol Ther 1996; 10: 875-82.
29. Grider JR, Foxx-Orenstein AE, Jin JG. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998; 115: 370-80.
30. Tutuian R, Castell DO. Effects of tegaserod on oesophageal bolus transport. Gut 2005 (Suppl VII): A52 [abstract].
31. Janiak P, Ghosh S, Hebbard G, et al. Changes in upper esophageal motor function in reflux esophagitis defined by high resolution manometry. Gastroenterology 2001; 120: A922 [abstract].
32. Rodriguez-Stanley S, Wolff M, Proskin H. An exploratory open label trial of tegaserod in non-erosive GERD patients with incomplete response to PPIs. Am J Gastroenterol 2005; 100: S-38 [abstract].